"Oligonucleotide therapies are scaling faster than the manufacturing base built for them."
As RNA-targeted therapies move from rare disease into broader indications, the specialized manufacturing they require hasn't kept pace. That gap is what's underwriting CDMO growth here.
Read the report behind this view
Oligonucleotide CDMO Market - Global Opportunity Analysis and Industry Forecast (2026-2036)